Teriflunomide is an immunomodulatory, disease-modifying oral drug with anti-inflammatory properties.
The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 patients with relapsing forms of MS and showed that the drug reduced the risk of annual relapses, disability progressions and disease activity, as compared to placebo.
The company has filed Teriflunomide with the FDA in August of 2011 and is expecting to file with the EMA in the first quarter of 2012.
The study has been published in The New England Journal of Medicine (NEJM).